Analysis

Updated June 5, 2026: Retatrutide has now completed Phase 3 trials for both obesity (TRIUMPH-1, 2,339 patients) and type 2 diabetes (TRANSCEND-T2D-1, 537 patients). Obesity: 28.3% weight loss at 80 weeks, 30.3% at 104 weeks, 65.3% achieved BMI <30. T2D: A1C −2.0%, weight −16.8% (36.6 lbs) at 40 weeks. Full datasets presenting at ADA June 6, 2026. NDA expected Q4 2026.

Clinical trials show 15–17% body weight loss with semaglutide over 68 weeks. Here's what to expect month by month, backed by data from the STEP trials.

IvyRx offers compounded semaglutide from $175/month and tirzepatide from $275/month with a rare flat-rate model — your price never increases as your dose goes up. We reviewed their pricing, clinical oversight, and transparency. Key finding: the flat-rate pricing is genuinely valuable, but IvyRx doesn't publicly disclose a named medical director or their compounding pharmacy partners, which are meaningful gaps for patients who want to verify clinical quality.

Updated June 1, 2026: CVS Caremark adds Foundayo to commercial formulary June 1 (~25–30M Americans newly covered); Medicare GLP-1 Bridge confirmed for Foundayo at $50/mo starting July 1. Week 6 IQVIA: ~17,000 weekly Rx (+66% WoW), cumulative ~45,000 Rx. Oral Wegovy produces 16.6% weight loss vs Foundayo's 12.4%; Foundayo starts at $149/mo self-pay with no fasting requirement.

Updated May 2026: 5 next-gen obesity drugs in Phase 3. Retatrutide (Lilly) 28.7% weight loss. CagriSema (Novo): REDEFINE-1 22.7% (obesity), REDEFINE-2 15.7% (T2D), PDUFA expected October 2026. MariTide (Amgen, monthly), survodutide, Foundayo approved April 2026. FDA approvals 2026-2028.

Verified April 2026: Zepbound and Mounjaro are the exact same drug (tirzepatide) at the same doses. Mounjaro was FDA-approved May 2022 for Type 2 diabetes. Zepbound was FDA-approved November 2023 for chronic weight management and December 2024 for obstructive sleep apnea. List price is ~$1,087/mo for both; with commercial insurance + savings cards both drop to $25/mo (max $1,950/yr). The real differences: which one your insurance covers, what the FDA label allows, and Zepbound's LillyDirect self-pay vials at $299-$449/mo — a program Mounjaro does not offer.

How much do GLP-1 medications cost in 2026? Wegovy, Zepbound, Ozempic, Mounjaro & Foundayo range from $25–$1,350/month. With insurance + savings card: $25/mo. Without insurance: $115/mo compounded sema (Enhance MD), $149/mo Foundayo pill, $299–449/mo brand injectable (LillyDirect, NovoCare). Medicare: $50/mo starting July 2026. Prices verified April 17, 2026 across 48 providers.

Verified April 2026: Brand-name Wegovy is $349/mo via NovoCare, Zepbound starts at $299/mo via LillyDirect. Compounded semaglutide is banned since Feb 2025; compounded tirzepatide remains legal at $149-299/mo under narrow medical-necessity rules. Full legal + safety comparison.

Verified April 2026: Zepbound (tirzepatide) produces 20.9% body weight loss vs Wegovy's (semaglutide) 14.9% per the SURMOUNT-1 and STEP-1 trials. Wegovy self-pay: $349/mo (NovoCare). Zepbound self-pay: $299-$449/mo (LillyDirect). Both $25/mo with commercial insurance + savings card.

Verified April 2026: Ozempic and Wegovy are both semaglutide from Novo Nordisk. Ozempic ($1,028/mo list) is approved for type 2 diabetes at max 2mg. Wegovy ($1,349/mo list) is approved for weight loss at max 2.4mg (or 7.2mg HD). Both drop to $349/mo self-pay via NovoCare.

Verified April 2026: Oral Wegovy (25mg daily pill) produces 16.6% weight loss per the OASIS trial vs 14.9% for injectable Wegovy (2.4mg weekly) per STEP-1. Pill costs $1,349/mo list vs $349/mo self-pay for the injection through NovoCare. Full head-to-head comparison.

Verified April 2026: Tirzepatide produces 20.2% weight loss vs semaglutide's 13.7% in the head-to-head SURMOUNT-5 trial (NEJM). Tirzepatide activates GLP-1 + GIP dual receptors; semaglutide activates GLP-1 only. Tirzepatide costs $449/mo vs $349/mo self-pay. Full comparison.

Verified April 2026: Tirzepatide costs $149/mo via Enhance MD (compounded), $299/mo via LillyDirect (brand Zepbound 2.5mg vial), $449/mo for LillyDirect 5mg+ vials, $25/mo with Zepbound savings card, or $1,086/mo retail list price. Full price breakdown with 47 verified providers.

Verified April 2026: Tirzepatide compounding enforcement began March 2025 after FDA removed it from the shortage list. Narrow medical-necessity exemptions still allow legal compounded tirzepatide at $149-300/mo (vs $1,086/mo retail Zepbound). Complete legal framework, safety, and verified pricing.

GLP-1 patches sold online don't contain semaglutide or tirzepatide — they're herbal supplements. Here's what the science says and what actually works.

Two of the biggest telehealth platforms now offer branded Wegovy and GLP-1 programs. We compare Ro and Hims on pricing, medications, insurance, clinical support, and what actually changed after the Novo Nordisk lawsuit.